meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
2
mUC - L2 - PDL1 positive
3
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab alone
title
pembrolizumab alone
title
Standard of Care (SoC)
title
IMvigor-211 (PDL1>5%), 2018 NCT02302807 mUC - L2 - PDL1 positive 116/118
IMvigor-211 (PDL1>1%), 2018 NCT02302807 mUC - L2 - PDL1 positive 316/309
KEYNOTE-045 (PDL1 CPS >10%), 2017 NCT02256436 mUC - L2 - PDL1 positive 74/90
Pathology:
mUC - L2 - PDL1 positive;
mUC - L2 - PDL1 positive
IMvigor-211 (PDL1>5%), 2018
IMvigor-211 (PDL1>1%), 2018
KEYNOTE-045 (PDL1 CPS >10%), 2017
atezolizumab alone
2
T1
T1
pembrolizumab alone
1
T1
Standard of Care (SoC)
0
T0
T0
T0